Table A3. All AEs Occurring in ≥ 5% of Patients in Any Study Arm in the DBT Period

AE (system organ class preferred term)	Placebo (n = 45)	Telotristat Ethyl (three times per day) 250 mg (n = 45)	500 mg (n = 45)	Total (N = 135)
GI disorders				
Nausea	5 (11.1)	6 (13.3)	14 (31.1)	25 (18.5)
Abdominal pain	8 (17.8)	5 (11.1)	10 (22.2)	23 (17.0)
Vomiting	4 (8.9)	2 (4.4)	5 (11.1)	11 (8.1)
Upper abdominal pain	0	2 (4.4)	5 (11.1)	7 (5.2)
Abdominal distension	3 (6.7)	2 (4.4)	1 (2.2)	6 (4.4)
Diarrhea	3 (6.7)	3 (6.7)	0	6 (4.4)
Flatulence	1 (2.2)	3 (6.7)	2 (4.4)	6 (4.4)
Dyspepsia	3 (6.7)	1 (2.2)	1 (2.2)	5 (3.7)
General disorders and administration site conditions				
Fatigue	4 (8.9)	4 (8.9)	7 (15.6)	15 (11.1)
Asthenia	3 (6.7)	2 (4.4)	1 (2.2)	6 (4.4)
Peripheral edema	1 (2.2)	3 (6.7)	1 (2.2)	5 (3.7)
Pyrexia	2 (4.4)	3 (6.7)	0	5 (3.7)
Infections and infestations				
Nasopharyngitis	1 (2.2)	2 (4.4)	3 (6.7)	6 (4.4)
Pneumonia	0	0	3 (6.7)	3 (2.2)
AEs relating to investigations				
Increased gamma-glutamyl transferase*	0	4 (8.9)	4 (8.9)	8 (5.9)
Increased ALT†	0	1 (22.2)	3 (6.7)	4 (3.0)
Increased alkaline phosphatase‡	0	0	3 (6.7)	3 (2.2)
Metabolism and nutrition disorders				
Decreased appetite	2 (4.4)	3 (6.7)	7 (15.6)	12 (8.9)
Hypokalemia	3 (6.7)	3 (6.7)	5 (11.1)	11 (8.1)
Nervous system disorders				
Headache	2 (4.4)	5 (11.1)	4 (8.9)	11 (8.1)
Dizziness	2 (4.4)	0	4 (8.9)	6 (4.4)
Memory impairment	3 (6.7)	0	1 (2.2)	4 (3.0)
Psychiatric disorders				
Depression-related§	3 (6.7)	3 (6.7)	7 (15.6)	13 (9.6)
Confusional state	0	0	3 (6.7)	3 (2.2)
Respiratory, thoracic, and mediastinal disorders				
Dyspnea	0	2 (4.4)	4 (8.9)	6 (4.4)
Cough	1 (2.2)	1 (2.2)	3 (6.7)	5 (3.7)
Epistaxis	0	0	3 (6.7)	3 (2.2)
Vascular disorders (new or worsening)				
Flushing	2 (4.4)	3 (6.7)	3 (6.7)	8 (5.9)

NOTE. Adverse events (AEs) were graded according to a standard severity grading scheme as mild, moderate, or severe. All data are presented as No. (%).
Abbreviation: DBT, double-blind treatment.
*Mean changes from baseline at week 12 in gamma-glutamyl transferase (U/L ± standard deviation [SD]) for all patients studied were 4.4 ± 31.6 in the placebo group, 130.0 ± 204.4 in the telotristat ethyl 250 mg three times per day group, and 242.4 ± 358.1 in the telotristat ethyl 500 mg three times per day group.
†Mean changes from baseline to week 12 in ALT (U/L ± SD) for all patients studied were –0.1 ± 6.2 in the placebo group, 7.1 ± 16.4 in the telotristat ethyl 250 mg three times per day group, and 17.4 ± 42.6 in the telotristat ethyl 500 mg three times per day group.
‡Mean changes from baseline to week 12 in alkaline phosphatase (U/L ± SD) for all patients studied were 16.1 ± 57.6 in the placebo group, 22.8 ± 41.8 in the telotristat ethyl 250 mg three times per day group, and 57.5 ± 140.8 in the telotristat ethyl 500 mg three times per day group.
§Depression-related AEs include depression, depressed mood, and decreased interest.

Table A3. All AEs Occurring in 5% of Patients in Any Study Arm in the DBT Period